Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience

被引:1
作者
Ekmekcioglu, Ozgul [1 ]
Yavuzsan, Abdullah Hizir [2 ]
Arican, Pelin [1 ]
Kirecci, Sinan Levent [2 ]
机构
[1] Univ Hlth Sci, Dept Nucl Med, Sisli Hamidiye Etfal Educ & Res Hosp, Halaskargazi Cad,Etfal Sokak, Istanbul, Turkey
[2] Univ Hlth Sci, Sisli Hamidiye Etfal Educ & Res Hosp, Dept Urol, Istanbul, Turkey
关键词
Ga-68; maximum standardized uptake value; prostate cancer; prostate-specific membrane antigen; RADICAL PROSTATECTOMY; ACCURACY; RISK; PSMA; PET;
D O I
10.4103/jcrt.JCRT_1223_20
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerized tomography (PET/CT) has been shown to have significant success in detecting local and distant metastases that cannot not be detected by conventional imaging. Initial staging in intermediate- and high-risk patients with prostate cancer is important for management. In addition, PSMA uptake has been shown to have a relation with grade of disease, and thus could be considered a separate noninvasive prognostic factor. In this study, we aimed to investigate the effect of PSMA PET/CT in the staging and management of prostate cancer patients as well as the relation to maximum standardized uptake value (SUVmax). Methods: The patients referred to our department for staging prostate cancer were evaluated retrospectively (n = 65). Patients were grouped as positive for lymph node or distant metastatic disease. Primary tumor SUVmax data were compared with the prognostic factors of the disease. In addition, decisions about treatment protocol before and after PSMA PET/CT imaging were noted. Results: All the patients except one were accepted as positive for primary tumor. Of the patients, 46.2% were positive for lymph node and 24.6% for distant metastases. After evaluation by PSMA PET/CT, the clinical choice of treatment changed for 43.1% of our patients. Primary tumor SUVmax and tumor-to-background SUVmax ratios were found to have a significant relation with D'Amico risk classification. We found a positive correlation between SUVmax and prostate-specific antigen, Gleason scores, and age. Conclusion: PSMA PET/CT images have a nonnegligible effect on staging, clinical decisions, and change in treatment protocol. SUVmax data have a positive correlation with risk classification and could be identified as a potential independent and non-invasive prognostic factor.
引用
收藏
页码:1351 / 1357
页数:7
相关论文
共 31 条
  • [1] Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
    Barakat, Andrew
    Yacoub, Basel
    El Homsi, Maria
    Aldine, Amro Saad
    El Hajj, Albert
    Haidar, Mohamad B.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [2] 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement
    Basha, Mohammad Abd Alkhalik
    Hamed, Maged Abdel Galil
    Hussein, Omar
    El-Diasty, Tarek
    Abdelkhalek, Yasser Ibrahim
    Hussein, Yehia Omar
    Alasamer, Ahmed Fathy
    Mohamed, Heba A. E.
    El Deen, Dalia Salah
    Tantawy, Engy Fathy
    Metwally, Maha Ibrahim
    Zaitoun, Mohamed M. A.
    Aly, Sameh Abdelaziz
    Altohamy, Jehan Ibrahim
    Mohamed, Abd El Motaleb
    Afifi, Amira Hamed Mohamed
    Harb, Ola
    [J]. ABDOMINAL RADIOLOGY, 2019, 44 (07) : 2545 - 2556
  • [3] BOSTWICK DG, 1994, AM J CLIN PATHOL, V102, pS38
  • [4] PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
    Bravaccini, Sara
    Puccetti, Maurizio
    Bocchini, Martine
    Ravaioli, Sara
    Celli, Monica
    Scarpi, Emanuela
    De Giorgi, Ugo
    Tumedei, Maria Maddalena
    Raulli, Giandomenico
    Cardinale, Loredana
    Paganelli, Giovanni
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [5] Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence
    Corcoran, Niall M.
    Hong, Matthew K. H.
    Casey, Rowan G.
    Hurtado-Coll, Antonio
    Peters, Justin
    Harewood, Laurence
    Goldenberg, S. Larry
    Hovens, Chris M.
    Costello, Anthony J.
    Gleave, Martin E.
    [J]. BJU INTERNATIONAL, 2011, 108 (8B) : E202 - E210
  • [6] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [7] Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis
    de Rooij, Maarten
    Hamoen, Esther H. J.
    Witjes, J. Alfred
    Barentsz, Jelle O.
    Rovers, Maroeska M.
    [J]. EUROPEAN UROLOGY, 2016, 70 (02) : 233 - 245
  • [8] Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
    Demirci, Emre
    Kabasakal, Levent
    Sahin, Onur E.
    Akgun, Elife
    Gultekin, Mehmet Hamza
    Doganca, Tunkut
    Tuna, Mustafa B.
    Obek, Can
    Kilic, Mert
    Esen, Tarik
    Kural, Ali R.
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (01) : 86 - 91
  • [9] Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology
    Donato, Peter
    Roberts, Matthew J.
    Morton, Andrew
    Kyle, Samuel
    Coughlin, Geoff
    Esler, Rachel
    Dunglison, Nigel
    Gardiner, Robert A.
    Yaxley, John
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 20 - 30
  • [10] PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics
    Eapen, R. S.
    Nzenza, T. C.
    Murphy, D. G.
    Hofman, M. S.
    Cooperberg, M.
    Lawrentschuk, N.
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (07) : 1255 - 1261